Scarica l'app Stockscreener
89.30
0.31%
0.28
Dopo l'orario di chiusura:
89.32
0.02
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Alcon Inc Borsa (ALC) Ultime notizie
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Phacoemulsification Devices Market Is Booming Worldwide - openPR.com
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stock News - GuruFocus
Citi more constructive on EU MedTech: Upgrades Demant; Alcon top pick - Investing.com Canada
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa
BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia
Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com Nigeria
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada
Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
US FDA approves Alcon's new dry-eye drug (May 28) - marketscreener.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
DOJ Requires Keysight to Shed Spirent Units Before $1.57 Billion Acquisition Proceeds - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):